Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer LA Rojas, Z Sethna, KC Soares, C Olcese, N Pang, E Patterson, J Lihm, ... Nature 618 (7963), 144-150, 2023 | 393 | 2023 |
ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity JA Moral, J Leung, LA Rojas, J Ruan, J Zhao, Z Sethna, A Ramnarain, ... Nature 579 (7797), 130-135, 2020 | 290 | 2020 |
Inferring processes underlying B-cell repertoire diversity Y Elhanati, Z Sethna, Q Marcou, CG Callan Jr, T Mora, AM Walczak Philosophical Transactions of the Royal Society B: Biological Sciences 370 …, 2015 | 215 | 2015 |
OLGA: fast computation of generation probabilities of B-and T-cell receptor amino acid sequences and motifs Z Sethna, Y Elhanati, CG Callan Jr, AM Walczak, T Mora Bioinformatics 35 (17), 2974-2981, 2019 | 184 | 2019 |
Predicting the spectrum of TCR repertoire sharing with a data‐driven model of recombination Y Elhanati, Z Sethna, CG Callan Jr, T Mora, AM Walczak Immunological reviews 284 (1), 167-179, 2018 | 126 | 2018 |
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer M Łuksza, ZM Sethna, LA Rojas, J Lihm, B Bravi, Y Elhanati, K Soares, ... Nature 606 (7913), 389-395, 2022 | 117 | 2022 |
Population variability in the generation and selection of T-cell repertoires Z Sethna, G Isacchini, T Dupic, T Mora, AM Walczak, Y Elhanati PLOS Computational Biology 16 (12), e1008394, 2020 | 53 | 2020 |
Insights into immune system development and function from mouse T-cell repertoires Z Sethna, Y Elhanati, CR Dudgeon, CG Callan Jr, AJ Levine, T Mora, ... Proceedings of the National Academy of Sciences 114 (9), 2253-2258, 2017 | 41 | 2017 |
Fundamental immune–oncogenicity trade-offs define driver mutation fitness D Hoyos, R Zappasodi, I Schulze, Z Sethna, KC de Andrade, DF Bajorin, ... Nature 606 (7912), 172-179, 2022 | 39 | 2022 |
Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma. VP Balachandran, LA Rojas, Z Sethna, K Soares, E Derhovanessian, ... Journal of Clinical Oncology 40 (16_suppl), 2516-2516, 2022 | 26 | 2022 |
Accelerating multidimensional NMR and MRI experiments using iterated maps MA Frey, ZM Sethna, GA Manley, S Sengupta, KW Zilm, JP Loria, ... Journal of Magnetic Resonance 237, 100-109, 2013 | 13 | 2013 |
Generative models of T-cell receptor sequences G Isacchini, Z Sethna, Y Elhanati, A Nourmohammad, AM Walczak, ... Physical Review E 101 (6), 062414, 2020 | 10 | 2020 |
GeneVector: Identification of transcriptional programs using dense vector representations defined by mutual information N Ceglia, Z Sethna, F Uhlitz, V Bojilova, N Rusk, B Burman, A Chow, ... bioRxiv, 2022.04. 22.487554, 2022 | 6 | 2022 |
RNA vaccines for cancer: Principles to practice P Guasp, C Reiche, Z Sethna, VP Balachandran Cancer Cell, 2024 | 1 | 2024 |
Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector N Ceglia, Z Sethna, SS Freeman, F Uhlitz, V Bojilova, N Rusk, B Burman, ... Nature Communications 14 (1), 4400, 2023 | 1 | 2023 |
Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness D Hoyos, R Zappasodi, I Schulze, Z Sethna, KC de Andrade, DF Bajorin, ... Nature 606 (7914), E5, 2022 | 1 | 2022 |
824 High quality neoantigens are immunoedited in long-term pancreatic cancer survivors Z Sethna, M Luksza, L Rojas, K Soares, J Leung, J Lihm, D Hoyos, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 1 | 2021 |
Characterizing the T cell response to a personalized cancer vaccine Z Sethna Bulletin of the American Physical Society, 2024 | | 2024 |
TCRi: Information theoretic metrics for single cell RNA and TCR sequencing in cancer N Ceglia, ZM Sethna, Y Elhanati, B Burman, A Chow, D Zamarin, ... bioRxiv, 2022.10. 01.510457, 2022 | | 2022 |
Fundamental immune-oncogenicity trade-offs define driver mutation fitness (vol 606, pg 172, 2022) D Hoyos, R Zappasodi, I Schulze, Z Sethna, KC de Andrade, DF Bajorin, ... Nature, 2022 | | 2022 |